Oncopeptides AB (publ) (ONCO.ST)
SEK 1.54
(1.18%)
SEK 1.54
(1.18%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -253.44 Million SEK | 25.83% |
| 2022 | -349.35 Million SEK | 75.41% |
| 2021 | -1.42 Billion SEK | 10.71% |
| 2020 | -1.59 Billion SEK | -115.21% |
| 2019 | -739.39 Million SEK | -76.34% |
| 2018 | -419.3 Million SEK | -69.33% |
| 2017 | -247.62 Million SEK | -116.3% |
| 2016 | -114.48 Million SEK | -114.59% |
| 2015 | -53.35 Million SEK | -61.13% |
| 2014 | -33.1 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -69.12 Million SEK | 12.67% |
| 2024 Q2 | -73.26 Million SEK | -6.0% |
| 2023 Q2 | -62.43 Million SEK | 14.17% |
| 2023 FY | -259.12 Million SEK | 25.83% |
| 2023 Q4 | -79.14 Million SEK | -112.2% |
| 2023 Q3 | -37.29 Million SEK | 40.26% |
| 2023 Q1 | -72.74 Million SEK | 27.66% |
| 2022 Q1 | -98.33 Million SEK | 74.78% |
| 2022 FY | -349.35 Million SEK | 75.41% |
| 2022 Q2 | -61.08 Million SEK | 37.88% |
| 2022 Q4 | -100.54 Million SEK | -13.16% |
| 2022 Q3 | -88.85 Million SEK | -45.45% |
| 2021 Q2 | -344.83 Million SEK | 0.72% |
| 2021 Q1 | -347.33 Million SEK | 32.11% |
| 2021 FY | -1.42 Billion SEK | 10.71% |
| 2021 Q3 | -338.91 Million SEK | 1.72% |
| 2021 Q4 | -389.83 Million SEK | -15.03% |
| 2020 Q2 | -399.33 Million SEK | -34.51% |
| 2020 FY | -1.59 Billion SEK | -115.21% |
| 2020 Q4 | -511.57 Million SEK | -33.4% |
| 2020 Q1 | -296.87 Million SEK | -21.55% |
| 2020 Q3 | -383.49 Million SEK | 3.97% |
| 2019 Q4 | -244.24 Million SEK | -28.82% |
| 2019 Q3 | -189.59 Million SEK | -10.4% |
| 2019 Q2 | -171.73 Million SEK | -40.85% |
| 2019 Q1 | -121.93 Million SEK | -9.64% |
| 2019 FY | -739.39 Million SEK | -76.34% |
| 2018 FY | -419.3 Million SEK | -69.33% |
| 2018 Q4 | -111.21 Million SEK | -7.99% |
| 2018 Q3 | -102.98 Million SEK | 28.02% |
| 2018 Q1 | -68.45 Million SEK | -2.62% |
| 2018 Q2 | -143.07 Million SEK | -109.02% |
| 2017 Q3 | -51.57 Million SEK | 23.32% |
| 2017 FY | -247.62 Million SEK | -116.3% |
| 2017 Q4 | -66.7 Million SEK | -29.34% |
| 2017 Q2 | -67.26 Million SEK | -8.34% |
| 2017 Q1 | -62.08 Million SEK | -21.52% |
| 2016 Q4 | -51.08 Million SEK | -107.11% |
| 2016 FY | -114.48 Million SEK | -114.59% |
| 2016 Q3 | -24.66 Million SEK | -5.04% |
| 2016 Q2 | -23.48 Million SEK | -54.05% |
| 2016 Q1 | -15.24 Million SEK | 0.0% |
| 2015 FY | -53.35 Million SEK | -61.13% |
| 2014 FY | -33.1 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | -1.793% |
| Ziccum AB (publ) | -21.56 Million SEK | -1075.543% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -1445.314% |
| BioArctic AB (publ) | 252.64 Million SEK | 200.319% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -29893.728% |
| Mendus AB (publ) | -100.65 Million SEK | -151.81% |
| Genovis AB (publ.) | 54.22 Million SEK | 567.407% |
| Intervacc AB (publ) | -93.57 Million SEK | -170.837% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -1533.877% |
| Active Biotech AB (publ) | -46.48 Million SEK | -445.235% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 1507.335% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -357.345% |
| Aptahem AB (publ) | -10.1 Million SEK | -2408.194% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 21.169% |
| Kancera AB (publ) | -65.04 Million SEK | -289.667% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | -88.273% |
| Fluicell AB (publ) | -26.87 Million SEK | -842.918% |
| Saniona AB (publ) | -81.06 Million SEK | -212.647% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -1948.719% |
| Biovica International AB (publ) | -126.07 Million SEK | -101.032% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -496.276% |
| AcouSort AB (publ) | -17.48 Million SEK | -1349.345% |
| Xintela AB (publ) | -57.23 Million SEK | -342.795% |
| Abliva AB (publ) | -96.54 Million SEK | -162.509% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 21.968% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -7131.013% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1493.806% |
| Amniotics AB (publ) | -29.07 Million SEK | -771.761% |
| 2cureX AB (publ) | -36.36 Million SEK | -596.991% |
| CombiGene AB (publ) | -36.3 Million SEK | -598.102% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -1631.195% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 34.066% |
| Camurus AB (publ) | 532.35 Million SEK | 147.609% |
| Corline Biomedical AB | -1.78 Million SEK | -14074.888% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | -40.208% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -508.034% |
| I-Tech AB | 24.43 Million SEK | 1137.229% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 67.857% |
| Cyxone AB (publ) | -21.66 Million SEK | -1070.061% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -139.18% |
| Biosergen AB | -27.26 Million SEK | -829.569% |
| Cantargia AB (publ) | -290.01 Million SEK | 12.61% |
| NextCell Pharma AB | -43.17 Million SEK | -487.062% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | -40.208% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -1382.469% |
| Nanologica AB (publ) | -69.96 Million SEK | -262.259% |
| SynAct Pharma AB | -224.49 Million SEK | -12.896% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -473.721% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -958.045% |
| LIDDS AB (publ) | -40.67 Million SEK | -523.118% |
| Lipum AB (publ) | -37.25 Million SEK | -580.322% |
| BioInvent International AB (publ) | -369.94 Million SEK | 31.49% |
| Alzinova AB (publ) | -16.52 Million SEK | -1433.997% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -3864.291% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -120.249% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -1158.489% |
| Simris Alg AB (publ) | -36.63 Million SEK | -591.817% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | -72.922% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 18.355% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -128.508% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -2091.311% |